Aparajita Verma1,2, Laurie J Rich1, Vui King Vincent-Chong1, Mukund Seshadri1,2,3. 1. Department of Oral Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA. 2. Department of Molecular and Cellular Biophysics and Biochemistry, Roswell Park Cancer Institute, Buffalo, NY, USA. 3. Department of Head and Neck Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA.
Abstract
BACKGROUND: The antidiabetic drug metformin (Met) is believed to inhibit tumor proliferation by altering the metabolism of cancer cells. In this study, we examined the effects of Met on tumor oxygenation, metabolism, and growth in head and neck squamous cell carcinoma (HNSCC) using non-invasive multimodal imaging. MATERIALS AND METHODS: Severe combined immunodeficient (SCID) mice bearing orthotopic FaDu HNSCC xenografts were treated with Met (200 mg/kg, ip) once daily for 5 days. Tumor oxygen saturation (%sO2 ) and hemoglobin concentration (HbT) were measured using photoacoustic imaging (PAI). Fluorescence imaging was employed to measure intratumoral uptake of 2-deoxyglucosone (2-DG) following Met treatment while magnetic resonance imaging (MRI) was utilized to measure tumor volume. Correlative immunostaining of tumor sections for markers of proliferation (Ki67) and vascularity (CD31) was also performed. RESULTS: At 5 days post-Met treatment, PAI revealed a significant increase (P < .05) in %sO2 and HbT levels in treated tumors compared to untreated controls. Fluorescence imaging at this time point revealed a 46% decrease in mean 2-DG uptake compared to controls. No changes in hemodynamic parameters were observed in mouse salivary gland tissue. A significant decrease in Ki-67 staining (P < .001) and MR-based tumor volume was also observed in Met-treated tumors compared to controls with no change in CD31 + vessel count following Met therapy. CONCLUSION: Our results provide, for the first time, direct in vivo evidence of Met-induced changes in tumor microenvironmental parameters in HNSCC xenografts. Our findings highlight the utility of multimodal functional imaging for non-invasive mapping of the effects of Met in HNSCC.
BACKGROUND: The antidiabetic drug metformin (Met) is believed to inhibit tumor proliferation by altering the metabolism of cancer cells. In this study, we examined the effects of Met on tumoroxygenation, metabolism, and growth in head and neck squamous cell carcinoma (HNSCC) using non-invasive multimodal imaging. MATERIALS AND METHODS: Severe combined immunodeficient (SCID) mice bearing orthotopic FaDu HNSCC xenografts were treated with Met (200 mg/kg, ip) once daily for 5 days. Tumoroxygen saturation (%sO2 ) and hemoglobin concentration (HbT) were measured using photoacoustic imaging (PAI). Fluorescence imaging was employed to measure intratumoral uptake of 2-deoxyglucosone (2-DG) following Met treatment while magnetic resonance imaging (MRI) was utilized to measure tumor volume. Correlative immunostaining of tumor sections for markers of proliferation (Ki67) and vascularity (CD31) was also performed. RESULTS: At 5 days post-Met treatment, PAI revealed a significant increase (P < .05) in %sO2 and HbT levels in treated tumors compared to untreated controls. Fluorescence imaging at this time point revealed a 46% decrease in mean 2-DG uptake compared to controls. No changes in hemodynamic parameters were observed in mouse salivary gland tissue. A significant decrease in Ki-67 staining (P < .001) and MR-based tumor volume was also observed in Met-treated tumors compared to controls with no change in CD31 + vessel count following Met therapy. CONCLUSION: Our results provide, for the first time, direct in vivo evidence of Met-induced changes in tumor microenvironmental parameters in HNSCC xenografts. Our findings highlight the utility of multimodal functional imaging for non-invasive mapping of the effects of Met in HNSCC.
Authors: David Adelstein; Maura L Gillison; David G Pfister; Sharon Spencer; Douglas Adkins; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; A Dimitrios Colevas; David W Eisele; Moon Fenton; Robert L Foote; Jill Gilbert; Robert I Haddad; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Debra Leizman; William M Lydiatt; Ellie Maghami; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; James Rocco; Cristina P Rodriguez; Jatin P Shah; Randal S Weber; Matthew Witek; Frank Worden; Sue S Yom; Weining Zhen; Jennifer L Burns; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2017-06 Impact factor: 11.908
Authors: Aisha A Hussein; Marco N Helder; Jan G de Visscher; C René Leemans; Boudewijn J Braakhuis; Henrica C W de Vet; Tymour Forouzanfar Journal: Eur J Cancer Date: 2017-06-24 Impact factor: 9.162
Authors: J Overgaard; H S Hansen; M Overgaard; L Bastholt; A Berthelsen; L Specht; B Lindeløv; K Jørgensen Journal: Radiother Oncol Date: 1998-02 Impact factor: 6.280
Authors: Vanessa E Zannella; Alan Dal Pra; Hala Muaddi; Trevor D McKee; Shawn Stapleton; Jenna Sykes; Rachel Glicksman; Selim Chaib; Paul Zamiara; Michael Milosevic; Bradly G Wouters; Robert G Bristow; Marianne Koritzinsky Journal: Clin Cancer Res Date: 2013-10-18 Impact factor: 12.531
Authors: Erica C Nakajima; Charles Laymon; Matthew Oborski; Weizhou Hou; Lin Wang; Jennifer R Grandis; Robert L Ferris; James M Mountz; Bennett Van Houten Journal: PLoS One Date: 2014-08-15 Impact factor: 3.240
Authors: Marina Domingo-Vidal; Diana Whitaker-Menezes; Cristina Martos-Rus; Patrick Tassone; Christopher M Snyder; Madalina Tuluc; Nancy Philp; Joseph Curry; Ubaldo Martinez-Outschoorn Journal: Mol Cancer Res Date: 2019-06-25 Impact factor: 5.852
Authors: Joseph M Curry; Jennifer Johnson; Mehri Mollaee; Patrick Tassone; Dev Amin; Alexander Knops; Diana Whitaker-Menezes; My G Mahoney; Andrew South; Ulrich Rodeck; Tingting Zhan; Larry Harshyne; Nancy Philp; Adam Luginbuhl; David Cognetti; Madalina Tuluc; Ubaldo Martinez-Outschoorn Journal: Front Oncol Date: 2018-10-11 Impact factor: 6.244